Robin Wenzel, head of Wells Fargo Industry Insights, said that the rise of GLP-1s has brought down the rate of bariatric surgery by more than 30%, providing a less invasive 'pharmaceutical offramp' for weight management. Wenzel said GLP-1 use rose 120% between 2022 and 2024 and that it offers th...
Source: [Bloomberg Markets](https://www.bloomberg.com/news/videos/2026-08-20/wells-fargo-report-glp-1s-reducing-certain-surgeries-video)